Skip to content
AnalystLens

IDEXX Laboratories Quarterly Report for Q1 Ended Mar 31, 2024

Filing Date
Filed May 1, 2024
Period End
March 31, 2024
Security
IDXX
One revenue dollarkept$0.24
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-Q filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories, Inc. reported solid financial results for the first quarter of 2024, with total revenue reaching $964.1 milliona, a 7.1% increase year-over-year.

This growth was primarily driven by its core Companion Animal Group (CAG) segment, which saw a 7.5% revenue increase, largely due to higher recurring revenue from diagnostics, consumables, and veterinary software and services. The company also demonstrated improved profitability, with gross profit rising 9.2% and income from operations increasing 6.6% to $299 millionb, reflecting an expanded gross margin of 61.5% compared to 60.3% in the prior year, aided by favorable sales mix and pricing. While the company continues to invest in growth, evidenced by a rise in R&D and G&A expenses, its financial position remains strong.

Net income increased by 10.1% to $235.6 millionc, resulting in diluted EPS of $2.81, up from $2.55 in the prior year. The company also maintained a healthy liquidity position, with $397.4 million in cash and cash equivalents and significant borrowing availability under its credit facility.

Notably, IDEXX repurchased $154.8 milliond of its common stock during the quarter, signaling confidence and a commitment to returning value to shareholders. The company expects continued growth, though it acknowledges potential headwinds from macroeconomic conditions and foreign currency fluctuations.

Key Highlights

  1. Total revenue increased by 7.1% year-over-year to $964.1 million, primarily driven by the Companion Animal Group (CAG).
  2. CAG segment revenue grew 7.5% to $889.3 million, fueled by recurring revenue from diagnostics and veterinary software/services.
  3. Gross profit increased by 9.2% to $593.1 million, with gross margin expanding to 61.5% from 60.3% in the prior year.
  4. Net income rose by 10.1% to $235.6 million, and diluted earnings per share (EPS) improved to $2.81 from $2.55 year-over-year.
  5. Operating expenses saw an increase, particularly in General and Administrative (G&A) and Research and Development (R&D), impacting operating income growth to 6.6%.
  6. The company repurchased $154.8 million of its common stock during the quarter.
  7. IDEXX maintained a strong liquidity position with $397.4 million in cash and cash equivalents and $998.5 million in available borrowing capacity under its credit facility.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2024, IDEXX Laboratories kept $0.24.

  1. Revenue$964.1M100.0%
  2. Cost of revenue−$371.0M38.5%
  3. Gross profit$593.1M61.5%
  4. Operating costs−$294.1M30.5%
  5. Operating income$299.0M31.0%
  6. Interest, other & tax−$63.4M6.6%
  7. Net income$235.6M24.4%
Computed from 10-QQ1 FY2024filed May 1, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2024 against Q1 FY2023

Line itemQ1 FY2024Q1 FY2023Change
Revenue$964.10M$900.20M+7.1%
Cost of Revenue$371.02M$357.22M+3.9%
Gross Profit$593.07M$542.97M+9.2%
R&D Expenses$52.63M$44.67M+17.8%
Operating Expenses$294.11M——
Operating Income$298.96M$280.40M+6.6%
Interest Expense$7.91M$13.13M−39.7%
Net Income$235.58M$214.05M+10.1%
EPS (Basic)$2.84$2.58+10.1%
EPS (Diluted)$2.81$2.55+10.2%
Shares Outstanding (Basic)83.10M82.99M+0.1%
Shares Outstanding (Diluted)83.96M83.96M0.0%

Frequently Asked Questions

  1. What was the primary driver of IDEXX's revenue growth in the first quarter of 2024?

    The primary driver of IDEXX's revenue growth was its Companion Animal Group (CAG) segment, which experienced a 7.5% increase in revenue. This growth was largely attributed to recurring revenue streams from diagnostics, consumables, and veterinary software and services, indicating strong demand and customer retention within the veterinary market.

  2. How did IDEXX's profitability change compared to the previous year?

    IDEXX showed improved profitability. Gross profit increased by 9.2% due to higher revenue and an expanded gross margin to 61.5% from 60.3%, driven by favorable sales mix and pricing strategies. While operating expenses, particularly in G&A and R&D, increased, net income still grew by 10.1% year-over-year.

  3. What is the company's financial health and liquidity situation?

    IDEXX maintains a strong financial position. As of March 31, 2024, the company had $397.4 million in cash and cash equivalents. It also has significant borrowing capacity available under its $1.25 billion credit facility, with $998.5 million in unused availability, providing ample resources to fund operations and growth initiatives.

  4. Has IDEXX returned capital to shareholders recently?

    Yes, IDEXX demonstrated a commitment to shareholder returns by repurchasing $154.8 million of its common stock during the first quarter of 2024. This action aims to offset dilution from share-based compensation and return value to shareholders.